AJC Urges Seattle to Act on Threats to Jewish Candidate

SEATTLE, June 11, 2019 /PRNewswire/ — American Jewish Committee (AJC) is urging Seattle leaders to condemn anti-Semitic threats against Ari Hoffman, a candidate for city council, and initiate steps to identify and prosecute those responsible for these hate crimes.

“Noxious threats against any candidate for elected office and his family are abhorrent, even more so when the venomous rhetoric is blatantly anti-Semitic,” said AJC Seattle Director Regina Friedland.

Hoffman and his family have been the subject of threatening postings on the notorious internet site 8chan, according to MEMRI, as well as on social media sites, ahead of the August 6 primary.

“Inaction has consequences,” said Friedland. “Whatever one may think about Mr. Hoffman’s policy positions on local Seattle issues, inserting his faith, or the State of Israel, into the discourse should be rebuked as out of bounds.”

Friedland called on Mayor Jenny Durkan to condemn unequivocally, without delay, the ongoing threats against Hoffman and his family, and for law enforcement authorities to initiate a criminal investigation into the threats.

Last month, the Seattle Office of City Auditor issued a new report on hate crimes in the city that showed an increase of nearly 25% over 2017.

AJC is a non-partisan organization that neither supports nor endorses candidates for elected office.

View original content:http://www.prnewswire.com/news-releases/ajc-urges-seattle-to-act-on-threats-to-jewish-candidate-300865881.html

SOURCE American Jewish Committee

Staff

Recent Posts

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX)…

1 hour ago

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…

19 hours ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…

19 hours ago

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

2 days ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

2 days ago